KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's Disease. PMID 39231444 · Inflamm Bowel Dis · 2025-Feb-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial. PMID 39910472 · BMC Cancer · 2025-Feb-05 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunction. PMID 39909533 · BMJ Open · 2025-Feb-05 This is a protocol for a randomized trial investigating the safety of withdrawing heart failure medication in cancer survivors. It lacks results, does not report a Phase III/IIIb or definitive Phase II/III trial, does not include a drug intervention for the cancer, and its primary endpoint is a safety/clinical outcome, not a time-to-event efficacy endpoint like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial. PMID 39909529 · BMJ Open · 2025-Feb-05 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of intermittent urethral catheter clamping combined with active urination training (ICCAUT) strategy on postoperative urinary dysfunction after radical rectal cancer surgery: single-centre randomised controlled trial (ICCAUT -1) study protocol. PMID 39909516 · BMJ Open · 2025-Feb-05 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. PMID 39798514 · Eur J Cancer · 2025-Feb-05 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
A new treatment strategy for mid-low rectal cancer patients exhibiting a clinical complete or near-complete response to neoadjuvant chemoradiotherapy: Transanal endoscopic microsurgery --A multicenter prospective case-control clinical trial by MONT-R. PMID 39693893 · Eur J Cancer · 2025-Feb-05 The study is a randomized, prospective, multicenter trial with human oncology patients and time-to-event efficacy endpoints (DFS, OS). However, the intervention is a surgical procedure (TEM) versus radical surgery, with no drug-containing intervention. The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, and the intervention is non-pharmacologic. Therefore, it fails the drug-intervention requirement and lacks definitive Phase III evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Can metformin prevent cancer relative to sulfonylureas? A target trial emulation accounting for competing risks and poor overlap via double/debiased machine learning estimators. PMID 39030720 · Am J Epidemiol · 2025-Feb-05 The record describes an observational pharmacoepidemiologic study (target trial emulation) comparing metformin to sulfonylureas for cancer incidence in a diabetes cohort. It is not a randomized clinical trial, not a Phase II/III study, and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) in an oncology therapeutic context. The endpoint is cancer incidence, which is a prevention outcome, not a therapeutic efficacy endpoint in a malignant neoplasm trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group. PMID 38995684 · Clin Infect Dis · 2025-Feb-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study. PMID 39905436 · Arthritis Res Ther · 2025-Feb-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Collagen turnover biomarkers to predict outcome of patients with biliary cancer. PMID 39905306 · BMC Gastroenterol · 2025-Feb-04 While the record is from a randomized oncology study with human participants and time-to-event endpoints, it is ineligible because it does not provide evidence of a Phase III/IIIb or Phase II/III trial, does not specify a drug-containing intervention, and is a biomarker analysis report rather than the formal efficacy report of a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19. PMID 39903535 · JCI Insight · 2025-Feb-04 The trial is a randomized, double-blind, placebo-controlled study of IL-7 in critically ill COVID-19 patients. It is human, includes a drug intervention, and reports original results. However, it is not an oncology study; it focuses on infectious disease (COVID-19). The primary endpoint is lymphocyte recovery, and secondary clinical endpoints are safety, length of stay, infections, and mortality. There is no mention of Kaplan-Meier analysis, hazard ratios, or other time-to-event efficacy endpoints for survival or disease progression. Therefore, it does not meet the oncology or time-to-event criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early Neurologic Deterioration and Efficacy of Dual Antiplatelet in Anterior Versus Posterior Circulation Stroke. PMID 39846303 · J Am Heart Assoc · 2025-Feb-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Protocol summary of a randomized phase III study: comparing systemic therapy with and without debulking surgery (primary tumour resection) for clinical stage IVA (cT1-2bN0-1M1a) non-small cell lung cancer with radiologically undetermined pleural dissemination JCOG2103 (DEBULK-LUNG). PMID 39444315 · Jpn J Clin Oncol · 2025-Feb-04 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Randomized phase III study comparing re-irradiation stereotactic body radiotherapy and conventional radiotherapy for painful spinal metastases: Japan Clinical Oncology Group study JCOG2211 (RESCORE study). PMID 39431960 · Jpn J Clin Oncol · 2025-Feb-04 The record is a protocol for a Phase III randomized oncology trial comparing radiotherapy techniques for painful spinal metastases. It meets the criteria for oncology, human, randomized, and phase3_or_definitive. However, it lacks a drug-containing intervention (radiotherapy is a device/modality, not a drug), and the abstract is a protocol without reported results. The primary endpoint (pain response at 12 weeks) could be considered a time-to-event endpoint in principle, but the abstract does not explicitly report time-to-event results (e.g., Kaplan-Meier, HR), and the deterministic_review signals 'time_to_event: false' and 'drug_intervention: false'. Therefore, it is excluded as not meeting the drug intervention requirement and lacking explicit time-to-event result reporting.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Multicenter randomized phase III study of high-dose therapy with autologous stem cell transplantation versus observation for patients with newly diagnosed peripheral T-cell lymphoma who achieved complete metabolic response after induction therapy (JCOG2210, TRANSFER study). PMID 39426803 · Jpn J Clin Oncol · 2025-Feb-04 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial. PMID 39400063 · J Infect Dis · 2025-Feb-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A randomized phase III study evaluating dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in patients with breast cancer. PMID 39354670 · Jpn J Clin Oncol · 2025-Feb-04 The record is a protocol abstract for a phase III randomized trial with a drug intervention, but it does not report results and the primary endpoint is not a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection. PMID 39172627 · J Infect Dis · 2025-Feb-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase 3 Study Assessing Lot-to-Lot Consistency of Respiratory Syncytial Virus Prefusion Protein F3 Vaccine and Its Immune Response, Safety, and Reactogenicity When Co-administered With Quadrivalent Influenza Vaccine. PMID 38970327 · J Infect Dis · 2025-Feb-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. PMID 38858818 · Nephrol Dial Transplant · 2025-Feb-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. PMID 40009381 · JAMA Netw Open · 2025-Feb-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Algorithm-Based Palliative Care in Patients With Cancer: A Cluster Randomized Clinical Trial. PMID 39982729 · JAMA Netw Open · 2025-Feb-03 Eligible for review as a human malignant-neoplasm randomized trial with original results, but excluded because it does not have a drug-containing intervention (intervention is algorithm-based palliative care process) and lacks a primary or key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. PMID 39960672 · JAMA Netw Open · 2025-Feb-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab. PMID 39901101 · J Headache Pain · 2025-Feb-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pathway Of Low Anterior Resection syndrome (LARS) relief after Surgery (POLARiS): protocol for an international, open-label, multi-arm, phase 3 randomised superiority trial within a cohort, with economic evaluation, process evaluation and qualitative sub-study, to explore the natural history of LARS and compare transanal irrigation and sacral neuromodulation to optimised conservative management for people with major LARS following a high or low anterior resection for colorectal cancer. PMID 39900423 · BMJ Open · 2025-Feb-03 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The effect of deep diaphragmatic breathing on fatigue in patients with metastatic gastrointestinal cancers: a randomized clinical trial. PMID 39899118 · Support Care Cancer · 2025-Feb-03 The study is a randomized oncology trial with human patients, but the intervention is a non-drug behavioral therapy (deep diaphragmatic breathing) and the primary endpoint is fatigue, not a time-to-event efficacy endpoint. Therefore, it does not meet the inclusion criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
177Lu-DOTATATE Plus Capecitabine Versus 177Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial. PMID 39778968 · J Nucl Med · 2025-Feb-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy. PMID 39527097 · Cancer Immunol Res · 2025-Feb-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Rationale and design of a multicentre randomised controlled trial on circulating tumour DNA-guided neoadjuvant treatment strategy for locally advanced rectal cancer (CINTS-R). PMID 39894522 · BMJ Open · 2025-Feb-02 This is a clinical trial protocol for a randomized controlled trial. While it meets criteria for oncology, human, randomized, time-to-event endpoints, and drug intervention, it is not a formal report of trial results. The trial phase is not explicitly stated in the title, abstract, or metadata as Phase III/IIIb or Phase II/III, and the deterministic review flagged phase3_evidence_unclear. Therefore, it is excluded as a protocol-without-results and due to insufficient evidence for the required phase.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Romosozumab improves microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis. PMID 39656908 · J Bone Miner Res · 2025-Feb-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses. PMID 39913230 · J Drugs Dermatol · 2025-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial. PMID 39892911 · Lancet · 2025-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis. PMID 39891702 · Cancer Immunol Immunother · 2025-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. PMID 39874977 · Lancet · 2025-Feb-01 命中用户提供的消化道肿瘤阳性参考集。
H L S B
旧组与严格 v3 交集 eligiblepositive_reference needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. PMID 39746212 · Obstet Gynecol · 2025-Feb-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine. PMID 39746206 · Obstet Gynecol · 2025-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial. PMID 39699905 · JAMA Oncol · 2025-Feb-01 命中用户提供的消化道肿瘤阳性参考集。
H L S B
旧组与严格 v3 交集 eligiblepositive_reference confirmed 1 Figure · 3 Panel · risk visible
Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy. PMID 39699886 · JAMA Ophthalmol · 2025-Feb-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The Effect of the Second Forward View on the Detection Rate of Sessile Serrated Lesions in the Proximal Colon: A Single-Center Prospective Randomized Controlled Study. PMID 39688959 · Clin Transl Gastroenterol · 2025-Feb-01 Study is a randomized trial in oncology (colorectal cancer screening) but does not meet eligibility criteria: it is not a Phase III drug trial and has no time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma. PMID 39660637 · Rhinology · 2025-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial. PMID 39602139 · JAMA Dermatol · 2025-Feb-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis. PMID 39547694 · J Rheumatol · 2025-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Final Results of the GRECCAR-6 Trial on Waiting Period Following Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer: 5 Years of Follow-up. PMID 39508462 · Dis Colon Rectum · 2025-Feb-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Automated patient selection and care coaches to increase advance care planning for patients with cancer. PMID 39348179 · J Natl Cancer Inst · 2025-Feb-01 The study is a cluster-randomized, stepped-wedge trial in oncology patients, but it is not a drug trial, does not report Phase III/IIIb or Phase II/III status, and its primary endpoint is a process measure (proportion of visits with prognosis documentation), not a time-to-event efficacy endpoint like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An Exploratory Analysis of the Conditional Neurocognitive Function Failure Risk in Patients Receiving Whole Brain Radiation Therapy for Brain Metastases on NRG Oncology CC001. PMID 39332644 · Int J Radiat Oncol Biol Phys · 2025-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. PMID 39332395 · JAMA Cardiol · 2025-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01). PMID 39326505 · Int J Radiat Oncol Biol Phys · 2025-Feb-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
The risk of treatment-related toxicities with PD-1/PD-L1 inhibitors in patients with lung cancer. PMID 39319530 · Int J Cancer · 2025-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial. PMID 39299550 · Int J Radiat Oncol Biol Phys · 2025-Feb-01 The record meets criteria for oncology, human, randomized, Phase 3, and time-to-event endpoints with original results. However, the drug intervention is not clearly established as a systemic drug therapy in the context of a Kaplan-Meier digitization cohort for drug-containing interventions. The intervention is a combination of a procedural technique (TACE) and radiation therapy (EBRT), which does not satisfy the requirement for a drug-containing intervention as defined by the adjudication rules.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -